ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • LPS
  • lubrication
  • Lung
  • lung and comorbidity
  • lung and ILC
  • lung and microparticles
  • lung and myositis
  • lung and pulmonary fibrosis
  • lung and rheumatoid arthritis
  • Lung and rheumatoid arthritis (RA)
  • lung and scleroderma
  • lung and scleroderma-like conditions
  • lung and systemic sclerosis
  • lung and tocilizumab
  • Lung and vasculitis
  • Lung Disease
  • Lung Disease and rheumatoid arthritis (RA)
  • Lung Disease and Sjogren's syndrome
  • Lung Disease and systemic lupus erythematosus (SLE)
  • Lung Disease and systemic sclerosis
  • Lung Fibrosis
  • lung injury
  • lung injury and methotrexate (MTX)
  • lung injury and scleroderma
  • lung transplant
  • lung transplantation and outcomes
  • lungs
  • Lupus
  • Lupus and activity score
  • Lupus and administrative databases
  • Lupus and adolescent patients
  • Lupus and anti-CCP antibodies
  • Lupus and antibodies
  • Lupus and antimalarial drugs
  • Lupus and arthritis
  • Lupus and arthroplasty
  • Lupus and atherosclerosis
  • Lupus and autoantibodies
  • Lupus and Autoinflammation
  • Lupus and avascular necrosis
  • Lupus and basic research
  • Lupus and belimumab
  • Lupus and biomarkers
  • Lupus and cancer
  • Lupus and cardiovascular disease
  • Lupus and clinical practice
  • Lupus and clinical trials
  • Lupus and communication
  • Lupus and community programs
  • Lupus and Compliance
  • Lupus and complications
  • Lupus and complimentary and alternative therapy
  • Lupus and corticosteroids
  • Lupus and Crosswalk
  • Lupus and cutaneous lupus
  • Lupus and cutaneous manifestations
  • Lupus and cyclophosphamide
  • Lupus and dendritic cells
  • Lupus and economics
  • Lupus and education
  • Lupus and environmental factors
  • Lupus and epidemiologic methods
  • Lupus and fibromyalgia
  • Lupus and genetic disorders
  • Lupus and genetics
  • Lupus and human papillomavirus (HPV)
  • Lupus and hydroxychloroquine
  • Lupus and immunodeficiency
  • Lupus and immunoglobulin (IG)
  • Lupus and infection
  • Lupus and interferons
  • Lupus and interleukins (IL)
  • Lupus and Kidney
  • Lupus and lupus nephritis
  • Lupus and metabolic syndrome
  • Lupus and microparticles
  • Lupus and morbidity and mortality
  • Lupus and mouse model
  • Lupus and myocardial involvement
  • Lupus and nephritis
  • Lupus and neuropathy
  • Lupus and neuropsychiatric disorders
  • Lupus and neutrophils
  • Lupus and obesity
  • Lupus and outcome measures
  • Lupus and outcomes
  • Lupus and pain
  • Lupus and pathogenesis
  • Lupus and pediatrics
  • Lupus and pharmacokinetics
  • Lupus and phenotypes
  • Lupus and physical activity
  • Lupus and plasma cells
  • Lupus and pregnancy
  • Lupus and primary care
  • Lupus and proteinuria
  • Lupus and Pulmonary Involvement
  • Lupus and quality improvement
  • Lupus and quality of life
  • Lupus and renal disease
  • Lupus and rheumatic disease
  • Lupus and Sexuality
  • Lupus and Sjogren's syndrome
  • Lupus and skin
  • Lupus and SLE
  • Lupus and social support
  • Lupus and stem cells
  • Lupus and Support and Education Groups
  • Lupus and systemic lupus erythematosus (SLE)
  • Lupus and T cells
  • Lupus and therapy
  • Lupus and thrombosis
  • Lupus and tobacco use
  • Lupus and toll-like receptors
  • Lupus and treatment
  • Lupus and tuberculosis
  • Lupus and Vitamin D
  • Lupus and weight loss
  • lupus anticoagulant
  • lupus arthritis
  • lupus dermatitis
  • lupus dermatitis and lymph node
  • lupus dermatitis and skin
  • Lupus nephritis
  • lupus nephritis and autoantibodies
  • lupus nephritis and biomarkers
  • lupus nephritis and bone density
  • lupus nephritis and complement
  • lupus nephritis and health disparities
  • lupus nephritis and lipids
  • lupus nephritis and longitudinal studies
  • lupus nephritis and Macrophage
  • lupus nephritis and macrophages
  • lupus nephritis and magnetic resonance imaging (MRI)
  • lupus nephritis and medication
  • Lupus nephritis and mesenchymal stem cells
  • lupus nephritis and meta-analysis
  • lupus nephritis and metabolism
  • lupus nephritis and metabolomics
  • lupus nephritis and microbiome
  • lupus nephritis and microparticles
  • lupus nephritis and monoclonal antibodies
  • lupus nephritis and morbidity and mortality
  • lupus nephritis and mouse model
  • lupus nephritis and mycophenolate mofetil
  • lupus nephritis and nephritis
  • lupus nephritis and neutrophils
  • lupus nephritis and obesity
  • lupus nephritis and osteoporosis
  • lupus nephritis and osteoprotegerin
  • lupus nephritis and outcome measures
  • lupus nephritis and outcomes
  • lupus nephritis and pathogenesis
  • lupus nephritis and patient
  • lupus nephritis and pediatric rheumatology
  • lupus nephritis and pediatrics
  • lupus nephritis and plasma cells
  • lupus nephritis and platelets
  • Lupus nephritis and prednisolone
  • lupus nephritis and prognostic factors
  • lupus nephritis and prolactin
  • lupus nephritis and proteinuria
  • lupus nephritis and proteomics
  • lupus nephritis and quality measures
  • lupus nephritis and quality of life
  • lupus nephritis and race/ethnicity
  • lupus nephritis and receptor for advanced glycation end product (RAGE)
  • lupus nephritis and regulatory cells
  • Lupus nephritis and remission
  • lupus nephritis and renal disease
  • lupus nephritis and rheumatic disease
  • lupus nephritis and risk assessment
  • lupus nephritis and rituximab
  • lupus nephritis and RNA sequencing
  • lupus nephritis and serum albumin
  • lupus nephritis and signal transduction
  • lupus nephritis and skin
  • Lupus nephritis and socioeconomic factors
  • lupus nephritis and systemic lupus erythematosus (SLE)
  • lupus nephritis and tacrolimus
  • lupus nephritis and th1
  • lupus nephritis and thrombosis
  • Lupus nephritis and time management
  • Lupus nephritis and transcription factor
  • lupus nephritis and transplantation
  • Lupus nephritis and treatment
  • lupus nephritis and tumor necrosis factor (TNF)
  • lupus nephritis and Urinary Biomarkers
  • lupus nephritis and viruses
  • lupus nephritis and vte
  • lupus treatment
  • lupus-like disease
  • Lyme disease
  • Lyme disease and pediatric rheumatology
  • Lyme disease and serologic tests
  • lymph
  • Lymph node
  • lymph node and lymphocytes
  • Lymph node and methotrexate (MTX)
  • lymph node and mucosal T cells
  • First |
  • « Previous Page
  • 31
  • 32
  • 33
  • 34
  • 35
  • [36]
  • 37
  • 38
  • 39
  • 40
  • 41
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology